What are the causes of elevated triglycerides in intensive care unit (ICU) patients?

Causes of Elevated Triglycerides in ICU Patients

In ICU patients, elevated triglycerides are primarily caused by propofol infusion and intravenous lipid emulsions used in parenteral nutrition, along with the acute inflammatory response and hyperinflammation associated with critical illness itself.

ICU-Specific Iatrogenic Causes

Propofol Sedation

• Propofol is the most significant iatrogenic cause of hypertriglyceridemia in ICU patients, with 18-21% of patients receiving continuous propofol infusions developing triglyceride levels >400 mg/dL 1, 2, 3, 4.
• Hypertriglyceridemia typically develops at a median of 54 hours after propofol initiation, though it can occur as early as 14 hours 4.
• The lipid emulsion vehicle in propofol provides 1.1 kcal/mL and represents a substantial non-nutritional calorie load that must be accounted for 5.
• Triglycerides should be monitored at least twice weekly in all patients receiving propofol infusions 5, 3.
• When hypertriglyceridemia is detected, propofol is discontinued within 24 hours in 84% of cases, with clinicians switching to alternative sedatives (midazolam, dexmedetomidine, or ketamine) in 70% of patients still requiring sedation 2, 4.

Parenteral Nutrition Lipid Emulsions

• Pure soy-based lipid emulsions should be limited during the first week in the ICU when acute inflammatory response is present, with preference for less inflammatory oils such as olive oil, medium-chain triglycerides (MCTs), and fish oil 5.
• Intravenous lipid emulsions require triglyceride monitoring, particularly when combined with propofol 5.
• Excessive lipid administration can lead to lipid overload, and high unsaturated fat can impair lung function and cause immune suppression 5.

Critical Illness-Related Metabolic Causes

Hyperinflammation and Cytokine Storm

• In COVID-19 patients and other critically ill patients, elevated triglycerides may indicate hyperinflammation as a secondary response to cytokine storm (secondary hemophagocytic lymphohistiocytosis) 5.
• Low plasma triglyceride levels are actually associated with improved survival in critical illness, while elevated levels correlate with worse outcomes 5.
• Infection and inflammation (measured by C-reactive protein) are independently associated with development of hypertriglyceridemia (r² = 0.19, p = 0.004) 3.

Altered Lipid Metabolism in Critical Illness

• Lipid metabolism is fundamentally modified in critical illness, with impaired fat absorption and altered clearance mechanisms 5.
• Endogenous glucose production is increased and does not decrease appropriately when nutrients and insulin are administered 5.

Secondary Medical Causes Common in ICU

Metabolic and Endocrine Disorders

• Diabetes mellitus with poor glycemic control is a major contributor, as hyperglycemia should be treated first before re-evaluating hypertriglyceridemia 5.
• Hypothyroidism, chronic liver disease, chronic kidney disease, and nephrotic syndrome all elevate triglycerides 5.
• Obesity and metabolic syndrome are frequently present in ICU patients with hypertriglyceridemia 5.

Medications Beyond Propofol

According to the AHA/ACC guidelines, triglyceride-raising drugs commonly used in ICU settings include 5:

• Immunosuppressive drugs (cyclosporine, sirolimus, tacrolimus)
• Glucocorticoids
• Thiazide diuretics
• Beta blockers
• Protease inhibitors (in HIV patients)
• Atypical antipsychotic drugs
• Interferon

Citrate in Continuous Renal Replacement Therapy

• Citrate use in continuous veno-venous hemodiafiltration (CVVH) is associated with increased carbohydrate load and should be accounted as non-nutritional calorie intake 5.

Clinical Implications and Monitoring

Risk of Pancreatitis

• Acute pancreatitis occurs in 1.2% of ICU patients receiving propofol, with higher rates (3.2%) in those with hypertriglyceridemia >400 mg/dL 1.
• Each 100 mg/dL increase in triglyceride levels is associated with an 11% increase in risk of pancreatitis 1.
• However, pancreatitis related to propofol-associated hypertriglyceridemia is relatively rare (occurring in only 10% of those with hypertriglyceridemia), indicating multifactorial pathophysiology 2.
• Pancreatitis can occur over a wide range of triglyceride levels, not just at extreme elevations 1.

Monitoring Strategy

• Close monitoring of triglycerides and liver function tests should guide clinicians in adjusting the glucose/lipid ratio in nutrition support 5.
• Triglyceride monitoring should occur at least twice weekly in patients on propofol 3.
• Electronic patient data management systems help recognize calorie overload from propofol and other sources 5.

Common Pitfall

The most critical pitfall is failing to account for propofol as a significant lipid source when calculating total caloric and fat intake, leading to unrecognized overfeeding and hypertriglyceridemia 5. Clinicians must sum all sources of lipids including propofol, parenteral nutrition lipid emulsions, and citrate from CVVH when assessing total caloric load.